Mantle cell lymphoma–advances in molecular biology, prognostication and treatment approaches
E Silkenstedt, K Linton… - British journal of …, 2021 - Wiley Online Library
Mantle cell lymphoma (MCL) is clinically characterised by its heterogenous behaviour with
courses ranging from indolent cases that do not require therapy for years to highly …
courses ranging from indolent cases that do not require therapy for years to highly …
Genomic profiling for clinical decision making in lymphoid neoplasms
With the introduction of large-scale molecular profiling methods and high-throughput
sequencing technologies, the genomic features of most lymphoid neoplasms have been …
sequencing technologies, the genomic features of most lymphoid neoplasms have been …
Treatment approaches for patients with TP53-mutated mantle cell lymphoma
Mantle cell lymphoma is an uncommon subtype of lymphoma characterised by clinical and
biological heterogeneity. Although most patients with mantle cell lymphoma have durable …
biological heterogeneity. Although most patients with mantle cell lymphoma have durable …
Soluble CD163 predicts outcome in both chemoimmunotherapy and targeted therapy–treated mantle cell lymphoma
A Nikkarinen, L Lokhande, RM Amini… - Blood …, 2023 - ashpublications.org
The outcome for patients with mantle cell lymphoma (MCL) has drastically improved with
new treatments directed toward the tumor immune microenvironment, where macrophages …
new treatments directed toward the tumor immune microenvironment, where macrophages …
Integrative analysis of clinicopathological features defines novel prognostic models for mantle cell lymphoma in the immunochemotherapy era: a report from The North …
JM Vose, K Fu, L Wang, A Mansoor, D Stewart… - Journal of Hematology & …, 2023 - Springer
Background Patients with mantle cell lymphoma (MCL) exhibit a wide variation in clinical
presentation and outcome. However, the commonly used prognostic models are outdated …
presentation and outcome. However, the commonly used prognostic models are outdated …
Comprehensive genetic analysis by targeted sequencing identifies risk factors and predicts patient outcome in Mantle Cell Lymphoma: results from the EU-MCL …
M Khouja, L Jiang, K Pal, PJ Stewart, B Regmi… - Leukemia, 2024 - nature.com
Recent studies highlighted genetic aberrations associated with prognosis in Mantle Cell
lymphoma (MCL), yet comprehensive testing is not implemented in clinical routine. We …
lymphoma (MCL), yet comprehensive testing is not implemented in clinical routine. We …
MYC protein is a high-risk factor in mantle cell lymphoma and identifies cases beyond morphology, proliferation and TP53/p53–a Nordic Lymphoma Group study
JM Rodrigues, P Hollander, L Schmidt, E Gkika… - …, 2023 - pmc.ncbi.nlm.nih.gov
The transcription factor MYC is a well-described oncogene with an important role in
lymphomagenesis, but its significance for clinical outcome in mantle cell lymphoma (MCL) …
lymphomagenesis, but its significance for clinical outcome in mantle cell lymphoma (MCL) …
Real-world routine diagnostic molecular analysis for TP53 mutational status is recommended over p53 immunohistochemistry in B-cell lymphomas
LM de Haan, RAL de Groen, FA de Groot… - Virchows Archiv, 2024 - Springer
Previous studies in patients with mature B-cell lymphomas (MBCL) have shown that
pathogenic TP53 aberrations are associated with inferior chemotherapeutic efficacy and …
pathogenic TP53 aberrations are associated with inferior chemotherapeutic efficacy and …
Accurate interpretation of p53 immunohistochemical patterns is a surrogate biomarker for TP53 alterations in large B-cell lymphoma
X Li, D Luo, L Zhang, Q Li, J Fan, J Zhang, B Huang… - BMC cancer, 2023 - Springer
Background To clarify the relationship between p53 immunohistochemistry (IHC) staining
and TP53 alterations (including mutations and deletions) in large B-cell lymphomas (LBCLs) …
and TP53 alterations (including mutations and deletions) in large B-cell lymphomas (LBCLs) …
Infiltration of CD163‐, PD‐L1‐and FoxP3‐positive cells adversely affects outcome in patients with mantle cell lymphoma independent of established risk factors
JM Rodrigues, A Nikkarinen… - British journal of …, 2021 - Wiley Online Library
We characterised patients with mantle cell lymphoma (MCL) with poor prognosis based on
differences in immune infiltration. Different expressions of the tumour cell markers Cyclin D1 …
differences in immune infiltration. Different expressions of the tumour cell markers Cyclin D1 …